Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Christgen

Showing results (91-100 of 107) with videos related to

Pageof 11
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2017
De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ETNadia Harbeck, Oleg Gluz, Matthias Christgen, et al.
Molecular Cancer|March 27, 2025
Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trialDarren Korbie, Clare Stirzaker, Oleg Gluz, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 20, 2025
In response to "Classification of Invasive Lobular Carcinoma"Maxim De Schepper, Thijs Koorman, François Richard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2022
De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN TrialOleg Gluz, Ulrike Nitz, Cornelia Kolberg-Liedtke, et al.
The Journal of Pathology. Clinical Research|April 15, 2024
Microenvironment-induced restoration of cohesive growth associated with focal activation of P-cadherin expression in lobular breast carcinoma metastatic to the colonMalte Gronewold, Isabel Grote, Stephan Bartels, et al.
The Journal of Clinical Investigation|July 24, 2025
A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and non-respondersGuokun Zhang, Vindi Jurinovic, Stephan Bartels, et al.
Journal of the National Cancer Institute|December 12, 2017
Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial ResultsOleg Gluz, Ulrike Nitz, Cornelia Liedtke, et al.
Journal of Cellular and Molecular Medicine|October 9, 2025
The Janus Face of SPAG6: Inducing EMT in Luminal Breast Cancer Cells Amidst Widespread Expression Loss in Breast TumoursAntonio Sechi, Jolein Mijnes, Sophia Villwock, et al.
JAMA Network Open|February 26, 2025
Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical TrialLisa Richters, Oleg Gluz, Nana Weber-Lassalle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2022
Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast CancerUlrike A Nitz, Oleg Gluz, Sherko Kümmel, et al.
Pageof 11

Showing results (91-100 of 107) with videos related to

Sort By:
Pageof 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2017
De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ETNadia Harbeck, Oleg Gluz, Matthias Christgen, et al.
Molecular Cancer|March 27, 2025
Immunomodulatory gene networks predict treatment response and survival to de-escalated, anthracycline-free neoadjuvant chemotherapy in triple-negative breast cancer in the WSG-ADAPT-TN trialDarren Korbie, Clare Stirzaker, Oleg Gluz, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 20, 2025
In response to "Classification of Invasive Lobular Carcinoma"Maxim De Schepper, Thijs Koorman, François Richard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2022
De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN TrialOleg Gluz, Ulrike Nitz, Cornelia Kolberg-Liedtke, et al.
The Journal of Pathology. Clinical Research|April 15, 2024
Microenvironment-induced restoration of cohesive growth associated with focal activation of P-cadherin expression in lobular breast carcinoma metastatic to the colonMalte Gronewold, Isabel Grote, Stephan Bartels, et al.
The Journal of Clinical Investigation|July 24, 2025
A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and non-respondersGuokun Zhang, Vindi Jurinovic, Stephan Bartels, et al.
Journal of the National Cancer Institute|December 12, 2017
Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial ResultsOleg Gluz, Ulrike Nitz, Cornelia Liedtke, et al.
Journal of Cellular and Molecular Medicine|October 9, 2025
The Janus Face of SPAG6: Inducing EMT in Luminal Breast Cancer Cells Amidst Widespread Expression Loss in Breast TumoursAntonio Sechi, Jolein Mijnes, Sophia Villwock, et al.
JAMA Network Open|February 26, 2025
Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical TrialLisa Richters, Oleg Gluz, Nana Weber-Lassalle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2022
Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast CancerUlrike A Nitz, Oleg Gluz, Sherko Kümmel, et al.
Pageof 11